Clinical Application
The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer
Yang Meng, Wang Jingjing, Deng Shaoqiong, Liang Sisi, Sun Li
Published 2024-07-23
Cite as Chin J Oncol, 2024, 46(7): 696-702. DOI: 10.3760/cma.j.cn112152-20231024-00224
Abstract
ObjectivesTo investigate the efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant ovarian cancer.
MethodsThirty-five patients with pathological confirmed platinum-resistant ovarian cancer who experienced progression after receiving at least two lines of standard treatment were eligible. All of them were treated with anlotinib combined with niraparib between September 2019 and October 2021. The primary endpoint was progression-free survival (PFS). The second endpoints included overall survival, objective response rate (ORR), disease control rate (DCR) and safety. Survival analysis was performed using the Kaplan-Meier method and Log-rank test, and influence factor analysis was performed using Cox proportional risk regression models.
ResultsThe best overall response showed that partial response was observed in 14 patients, stable disease was noted within 13 patients, and progressive disease was found in 8 patients. Therefore, the ORR and DCR of these 35 patients were 40.0% (95% CI:22.9%-57.1%) and 77.1% (95% CI:62.9%-91.4%), respectively. The median follow-up duration was 18.9 months (6.9-32.2). The median PFS was 6.5 months (95% CI:5.35-7.66). Multivariate Cox regression analysis for PFS indicated that age, Eastern Cooperative Oncology Group performance status (ECOG PS) score, International Federation of Gynecology and Obstetrics (FIGO) stage, and BRCA mutation status were independent factors influencing PFS (P＜0.05). Additionally, the PFS in patients with BRCA mutation who have never received PARP inhibitor treatment was significantly longer than that in patients without BRCA mutation who have been exposed to prior PARPi treatment (15.0 vs 6.0 month, P=0.029). The most common treatment-related adverse reactions were fatigue (85.7%), hematologic toxic (85.7%) and hypertension (74.3%). There were no treatment-related deaths.
ConclusionAnlotinib combined with niraparib shows a promising efficacy and tolerable safety in platinum-resistant ROC patients.
Key words:
Ovarian neoplasms; Platinum resistance; Anlotinib; Niraparib; Efficacy; Safety
Contributor Information
Yang Meng
Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital &
Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China
Wang Jingjing
Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital &
Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China
Deng Shaoqiong
Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital &
Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China
Liang Sisi
Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital &
Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China
Sun Li
Department of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
